Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly

Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly  Reuters

Summary aggregated from Reuters's public RSS feed. The full reporting belongs to Reuters — please read it on their site.